Results 171 to 180 of about 8,134 (194)

Tolvaptan

Reactions Weekly, 2016
openaire   +2 more sources

Tolvaptan

Drugs of the Future, 2002
null Sorbera, L.A., null Castaner, J., null Bayes, M., null Silvestre, J.   +3 more
openaire   +1 more source

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of Clinical Pharmacology, 2011
Suresh Mallikaarjun
exaly  

Mechanisms of tolvaptan-induced toxicity in HepG2 cells

Biochemical Pharmacology, 2015
Yuanfeng Wu, Frederick A Beland, Si Chen
exaly  

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

British Journal of Clinical Pharmacology, 2012
Suresh Mallikaarjun
exaly  

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety, 2015
Paul B Watkins, Neil Kaplowitz, Vicente E Torres   +2 more
exaly  

Tolvaptan

Reactions Weekly, 2012
openaire   +1 more source

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Toxicological Sciences, 2017
William J Brock, Kim L R Brouwer, Rachel J Church   +2 more
exaly  

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

Clinical and Experimental Nephrology, 2015
Satoru Muto, Eiji Higashihara, Ichiei Narita   +2 more
exaly  

Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites

Hepatology Research, 2017
Tomomi Kogiso
exaly